TY - JOUR
T1 - Abdominal pain in patients with inflammatory bowel disease in remission
T2 - A prospective study on contributing factors
AU - Janssen, L M
AU - Rezazadeh Ardabili, A
AU - Romberg-Camps, M J L
AU - Winkens, B
AU - van den Broek, R J
AU - Hulst, J
AU - Verwijs, H J A
AU - Keszthelyi, D
AU - Jonkers, D M A E
AU - van Bodegraven, A A
AU - Pierik, M J
AU - Mujagic, Z
PY - 2023/11
Y1 - 2023/11
N2 - BACKGROUND: Abdominal pain is highly prevalent in patients with inflammatory bowel disease (IBD) in remission, but the aetiology is incompletely understood. AIM: To investigate the association of clinical, lifestyle and psychosocial factors with abdominal pain in patients with IBD in remission. METHODS: We performed a prospective multicentre study enrolling consecutive patients with IBD. Data were collected between 1 January 2020 and 1 July 2021, using myIBDcoach, an established remote monitoring platform for IBD. Chronic abdominal pain in IBD in remission (IBDremissionPain+) was defined as abdominal pain score =3 (0-10 NRS) on =1/3 of all assessments, combined with faecal calprotectin <150?µg/g in 90?days around periodic assessments. Disease activity, lifestyle and psychosocial factors were assessed every 1-3?months during 18?months. Using linear mixed models, the association of these factors with abdominal pain over time was analysed. RESULTS: We included 559 patients, of whom 429 (76.7%) remained in biochemical remission. Of these, 198 (46.2%) fulfilled the criteria for chronic abdominal pain. IBDremissionPain+ patients were characterised by female sex, younger age, higher BMI, and shorter disease duration. They reported more often or higher levels of stress, fatigue, depressive and anxiety symptoms, and life events (all p?<?0.001). In the multivariable analysis, sex, disease entity, fatigue, depressive symptoms and life events were associated with abdominal pain over time (all p?<?0.05). CONCLUSION: In this cohort of patients with IBD in remission, abdominal pain was common and associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.
AB - BACKGROUND: Abdominal pain is highly prevalent in patients with inflammatory bowel disease (IBD) in remission, but the aetiology is incompletely understood. AIM: To investigate the association of clinical, lifestyle and psychosocial factors with abdominal pain in patients with IBD in remission. METHODS: We performed a prospective multicentre study enrolling consecutive patients with IBD. Data were collected between 1 January 2020 and 1 July 2021, using myIBDcoach, an established remote monitoring platform for IBD. Chronic abdominal pain in IBD in remission (IBDremissionPain+) was defined as abdominal pain score =3 (0-10 NRS) on =1/3 of all assessments, combined with faecal calprotectin <150?µg/g in 90?days around periodic assessments. Disease activity, lifestyle and psychosocial factors were assessed every 1-3?months during 18?months. Using linear mixed models, the association of these factors with abdominal pain over time was analysed. RESULTS: We included 559 patients, of whom 429 (76.7%) remained in biochemical remission. Of these, 198 (46.2%) fulfilled the criteria for chronic abdominal pain. IBDremissionPain+ patients were characterised by female sex, younger age, higher BMI, and shorter disease duration. They reported more often or higher levels of stress, fatigue, depressive and anxiety symptoms, and life events (all p?<?0.001). In the multivariable analysis, sex, disease entity, fatigue, depressive symptoms and life events were associated with abdominal pain over time (all p?<?0.05). CONCLUSION: In this cohort of patients with IBD in remission, abdominal pain was common and associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.
U2 - 10.1111/apt.17718
DO - 10.1111/apt.17718
M3 - Article
SN - 0269-2813
VL - 58
SP - 1041
EP - 1051
JO - Alimentary Pharmacology & Therapeutics
JF - Alimentary Pharmacology & Therapeutics
IS - 10
ER -